Piperazine-Fused 1,2-Dithiane ADC Linkers for Selective Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates face challenges with cleavable units that lack extracellular stability and efficient intracellular payload release, particularly in large biomolecular constructs, leading to systemic side effects and reduced efficacy.
Innovation Solution
Incorporation of bicyclic piperazine-fused 1,2-dithianes as cleavable units in immunoconjugates, which provide fast, high-turnover intracellular reductive cleavage and resistance to extracellular hydrolysis and reduction, allowing modular integration with self-immolative spacers and bioconjugation warheads.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cleavable units are used in immunoconjugates, then the therapeutic payload can be released intracellularly, but the cleavable units lack extracellular stability and undergo premature cleavage
Solution Approach 1:
The patent changes the chemical structure of the cleavable unit from conventional linear disulfides to bicyclic piperazine-fused 1,2-dithianes, fundamentally altering the molecular geometry and electronic properties. This structural parameter change confers both extracellular stability (resistance to hydrolysis and reduction) and efficient intracellular reductive cleavage capability, resolving the contradiction between stability and release efficiency
Solution Approach 2:
The invention creates a composite functional unit combining the piperazine-fused 1,2-dithiane core with self-immolative spacer moieties and bioconjugation warheads. This composite architecture integrates multiple functions: structural stability, redox-responsive cleavage, and efficient payload release, simultaneously achieving both extracellular robustness and intracellular activity
2Productivity
If highly bioactive therapeutic payloads are used, then therapeutic efficacy is improved, but systemic side effects increase
Solution Approach 1:
The patent employs the bicyclic piperazine-fused 1,2-dithiane cleavable unit as an intermediary that controls the release timing and location of the therapeutic payload. This intermediary structure ensures the potent payload remains bound during circulation (minimizing systemic exposure) but releases efficiently upon intracellular reduction (maximizing therapeutic efficacy at the target site)
Solution Approach 2:
The immunoconjugate system performs self-service through the autonomous reductive cleavage of the piperazine-fused 1,2-dithiane unit upon entry into target cells. This self-triggered mechanism eliminates the need for external intervention to activate the payload, ensuring selective release only at the target site while maintaining stability throughout circulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ensures selective delivery of therapeutic payloads to target cells with reduced off-target release, enhancing therapeutic efficacy and minimizing systemic side effects.
Implementation Method 1
releasing a molecular cargo in the presence of a reductant
Data Source
AI summary
The present application relates to a multicomponent immunoconjugate that is capable of targeting a cellular environment and releasing a molecular cargo in the presence of a reductant, and is thus suitable for treating, ameliorating or preventing a disorder selected from a neoplastic disorder, particularly cancer; atherosclerosis; an autoimmune disorder; an inflammatory disease; and a chronic inflammatory autoimmune disease. Precursors of the immunoconjugate are also disclosed.